Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Clinical experience suggests compounded versions produce equivalent results in terms of weight loss, glucose control, and other benefits
Irritation here causes more discomfort than elsewhere and can affect vision temporarily
It preserves and protects the brain and other body tissues from the damage of free radicals
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
